

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,

b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14,

c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and

d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.

2. (Withdrawn) An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.

3. (Currently Amended) An isolated polynucleotide encoding a polypeptide of claim 1 ~~comprising an amino acid sequence selected from the group consisting of:~~

- a) SEQ ID NO: 2;
- b) an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2 and having synthetase activity;
- c) a biologically active fragment of SEQ ID NO: 2 having synthetase activity; and
- d) an immunogenic fragment of SEQ ID NO: 2.

4. (Currently Amended) ~~An~~ The isolated polynucleotide ~~encoding a polypeptide of~~ claim 2 3, wherein the polynucleotide encodes SEQ ID NO: 2.

5. (Currently Amended) ~~An~~ The isolated polynucleotide of claim 4, wherein the polynucleotide is selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29.

6. (Original) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. (Original) A cell transformed with a recombinant polynucleotide of claim 6.

8. (Withdrawn) A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. (Withdrawn) A method for producing a polypeptide of claim 1, the method comprising:

- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

- b) recovering the polypeptide so expressed.

10. (Withdrawn) An isolated antibody which specifically binds to a polypeptide of claim 1.

11. (Currently Amended) An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- a) ~~a polynucleotide sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,~~
- b) ~~a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17 and encoding a polypeptide having synthetase activity, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,~~
- c) a polynucleotide sequence complementary to a),
- d) a polynucleotide sequence complementary to b), and
- e) an RNA equivalent of a)-d).

12. (Original) An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. (Withdrawn) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under

conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. (Withdrawn) A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. (Withdrawn) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. (Withdrawn) A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. (Withdrawn) A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.

18. (Withdrawn) A method for treating a disease or condition associated with decreased expression of functional SYNT, comprising administering to a patient in need of such treatment the composition of claim 16.

19. (Withdrawn) A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. (Withdrawn) A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. (Withdrawn) A method for treating a disease or condition associated with decreased expression of functional SYNT, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 20.

22. (Withdrawn) A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. (Withdrawn) A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. (Withdrawn) A method for treating a disease or condition associated with overexpression of functional SYNT, comprising administering to a patient in need of such treatment a composition of claim 23.

25. (Withdrawn) A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. (Withdrawn) A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim I with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim I in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. (Withdrawn) A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and
- b) detecting altered expression of the target polynucleotide.

28. (Withdrawn) A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein

a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

29. (Withdrawn) A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound under conditions suitable for the expression of the target polynucleotide.
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

30. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

31. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

32. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

33. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

34. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

35. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

36. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

37. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

38. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

39. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

40. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

41. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

42. (Withdrawn) A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

43. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:16.

44. (Original) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:17.

45. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:19.

46. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:20.

47. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:21.

48. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO 22.

49. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:23.

50. (Withdrawn) A polynucleotide of claim ii. comprising the polynucleotide sequence of SEQ ID NO:24.

51. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:25.

52. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:26.

53. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:27.

54. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:28.

55. (Withdrawn) A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:29.

56. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:1.

57. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:2.

58. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:4.

59. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:5.

60. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:6.

61. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:7.

62. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:8.

63. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:9.

64. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:10.

65. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:11.

66. (Withdrawn) A method of claim 9. wherein the polypeptide has the sequence of SEQ ID NO:12.

67. (Withdrawn) A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:13.

68. (Withdrawn) A method of claim 9. wherein the polypeptide has the sequence of SEQ ID NO:14.

69. (Withdrawn) A diagnostic test for a condition or disease associated with the expression of human synthetases (SYNT) in a biological sample comprising the steps of:

- a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

70. (Withdrawn) The antibody of claim 10, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a F(ab')₂ fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

71. (Withdrawn) A composition comprising an antibody of claim 10 and an acceptable excipient.

72. (Withdrawn) A method of diagnosing a condition or disease associated with the expression of human synthetases (SYNT) in a subject, comprising administering to said subject an effective amount of the composition of claim 71.

73. (Withdrawn) A composition of claim 71, wherein the antibody is labeled.

74. (Withdrawn) A method of diagnosing a condition or disease associated with the expression of human synthetases (SYNT) in a subject, comprising administering to said subject an effective amount of the composition of claim 73.

75. (Withdrawn) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibodies from said animal; and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.

76. (Withdrawn) An antibody produced by a method of claim 75.

77. (Withdrawn) A composition comprising the antibody of claim 76 and a suitable carrier.

78. (Withdrawn) A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5,

SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

- b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
- d) culturing the hybridoma cells; and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.

79. (Withdrawn) A monoclonal antibody produced by a method of claim 78.

80. (Withdrawn) A composition comprising the antibody of claim 79 and a suitable carrier.

81. (Withdrawn) The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

82. (Withdrawn) The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

83. (Withdrawn) A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, in a sample comprising the steps of:

- a) incubating the antibody of claim 10 with a sample under conditions to allow

specific binding of the antibody and the polypeptide; and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, in the sample.

84. (Withdrawn) A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, from a sample the method comprising:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14.

85. (Original) A microarray wherein at least one element of the microarray is a polynucleotide of claim 12.

86. (Withdrawn) A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of:

a) labeling the polynucleotides of the sample.

b) contacting the elements of the microarray of claim 85 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex. and

c) quantifying the expression of the polynucleotides in the sample.

87. (Original) An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide. said target polynucleotide having a sequence of claim 11.

88. (Original) An array of claim 87, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

89. (Original) An array of claim 87, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

90. (Original) An array of claim 87, which is a microarray.

91. (Original) An array of claim 87, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.

92. (Original) An array of claim 87, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

93. (Original) An array of claim 87. wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence. and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.

94. (New) The polynucleotide of claim 3, wherein said polynucleotide encodes an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2.

95. (New) The isolated polynucleotide of claim 11, wherein said polynucleotide sequence has at least 95% sequence identity to SEQ ID NO: 17.